A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses

Chun Jung Chang, Yao Hsu Yang, Yu Chih Liang, Chiao Juno Chiu, Kuan Hua Chu, Hung Non Chou, Bor Luen Chiang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.

Original languageEnglish
Pages (from-to)15-25
Number of pages11
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume183
Issue number1
DOIs
Publication statusPublished - Jan 1 2011

Fingerprint

Phycobiliproteins
Phycocyanin
Inflammation
Interleukin-12
Dendritic Cells
Ovalbumin
Cultured Cells
Asthma
T-Lymphocytes
Toll-Like Receptor 4
MAP Kinase Signaling System
Leukotrienes
Histamine Release
Bronchoalveolar Lavage Fluid
Electrophoretic Mobility Shift Assay
Endocytosis
Eosinophils
Interferons
Immunoglobulin E
Disease Progression

Keywords

  • Allergic asthma
  • Immunomodulation
  • R-phycocyanin
  • Th1

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses. / Chang, Chun Jung; Yang, Yao Hsu; Liang, Yu Chih; Chiu, Chiao Juno; Chu, Kuan Hua; Chou, Hung Non; Chiang, Bor Luen.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 183, No. 1, 01.01.2011, p. 15-25.

Research output: Contribution to journalArticle

Chang, Chun Jung ; Yang, Yao Hsu ; Liang, Yu Chih ; Chiu, Chiao Juno ; Chu, Kuan Hua ; Chou, Hung Non ; Chiang, Bor Luen. / A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses. In: American Journal of Respiratory and Critical Care Medicine. 2011 ; Vol. 183, No. 1. pp. 15-25.
@article{8928311dc3814068ae0fb26547a6279d,
title = "A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses",
abstract = "Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.",
keywords = "Allergic asthma, Immunomodulation, R-phycocyanin, Th1",
author = "Chang, {Chun Jung} and Yang, {Yao Hsu} and Liang, {Yu Chih} and Chiu, {Chiao Juno} and Chu, {Kuan Hua} and Chou, {Hung Non} and Chiang, {Bor Luen}",
year = "2011",
month = "1",
day = "1",
doi = "10.1164/rccm.201001-0009OC",
language = "English",
volume = "183",
pages = "15--25",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - A novel phycobiliprotein alleviates allergic airway inflammation by modulating immune responses

AU - Chang, Chun Jung

AU - Yang, Yao Hsu

AU - Liang, Yu Chih

AU - Chiu, Chiao Juno

AU - Chu, Kuan Hua

AU - Chou, Hung Non

AU - Chiang, Bor Luen

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.

AB - Rationale: It has been claimed that phycocyanin exhibits pharmaceutical functions in inhibiting histamine release and leukotriene biosynthesis. In allergic asthma, these inflammatory mediators are crucial for disease progression. Objectives: The aim of this study was to evaluate the therapeutic potential of R-phycocyanin (R-PC) against allergic airway inflammation. Methods: Mousebone marrow - derived dendritic cells (BMDCs)were used to evaluate the immunomodulatory functions of R-PC. In addition, an airway inflammatory model was used to evaluate the therapeutic potential of R-PC. Measurements and Main Results: R-PC treatment resulted in a decrease of endocytosis, increase of costimulatory molecule expression, and enhancement of interleukin-12 production in mouse BMDCs. Moreover, R-PC - treated cultured dendritic cells were able to promote CD4+ T-cell stimulatory capacity and increase interferon-γ expression in CD4+ T cells. Intraperitoneal administration of R-PC suppressed ovalbumin (OVA)-induced airway hyperresponsiveness, serum levels of OVA-specific IgE and IgG1, eosinophil infiltration, Th2 cytokine levels, and eotaxin in bronchoalveolar lavage fluid of mice. Antibody against Toll-like receptor-4 was able to inhibit R-PC - induced IL-12 p70 production. Moreover, inhibition of nuclear factor-κB (NF-κB) by helenalin and inhibition of the JNK pathway by JNK inhibitor II inhibited R-PC - induced IL-12 p70 production. Western blotting and electrophoretic mobility shift assays showed that R-PC augmented phosphorylation of the inhibitors of NF-κB and inhibitors of NF-κB kinase and facilitated NF-κB activity. Conclusions: Our data demonstrated that R-PC promoted activation and maturation of cultured dendritic cells and skewed the immunological function toward Th1 activity. Therefore, R-PC may have potential in regulating immune responses and application in reducing allergic asthma.

KW - Allergic asthma

KW - Immunomodulation

KW - R-phycocyanin

KW - Th1

UR - http://www.scopus.com/inward/record.url?scp=78650791241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650791241&partnerID=8YFLogxK

U2 - 10.1164/rccm.201001-0009OC

DO - 10.1164/rccm.201001-0009OC

M3 - Article

C2 - 20709826

AN - SCOPUS:78650791241

VL - 183

SP - 15

EP - 25

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -